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The  number  of  genes  known  to cause  human  monogenic  diseases  is increasing  rapidly.  For the  extremely
large,  genetically  and phenotypically  heterogeneous  group  of  intellectual  disability  (ID)  disorders,  more
than  600 causative  genes  have  been  identiﬁed  to date. However,  knowledge  about  the molecular  mech-
anisms  and  networks  disrupted  by  these  genetic  aberrations  is lagging  behind.  The  fruit  ﬂy Drosophila
has  emerged  as a powerful  model  organism  to  close  this  knowledge  gap.  This  review  summarizes  recent
achievements  that  have  been  made  in  this  model  and  envisions  its  future  contribution  to our under-
standing  of  ID genetics  and  neuropathology.  The  available  resources  and efﬁciency  of Drosophila  place
it in  a  position  to  tackle  the  main  challenges  in  the  ﬁeld:  mapping  functional  modules  of  ID genes  to
provide  conceptually  novel  insights  into  the  genetic  control  of  cognition,  tailored  functional  studies  to
improve  ‘next-generation’  diagnostics,  and  identiﬁcation  of  reversible  ID phenotypes  and  medication.
Drosophila’s  behavioral  repertoire  and  powerful  genetics  also  open  up  perspectives  for modeling  genet-
ically  complex  forms  of  ID  and  neuropsychiatric  disorders,  which  overlap  in their genetic  etiologies.  In
conclusion,  Drosophila  provides  many  opportunities  to advance  future  medical  genomics  of  early  onset
cognitive  disorders.endrites
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. Introduction
The human brain is one of nature’s most sophisticated struc-
ures. During brain development, billions of neurons are born and
rganized into complex networks. Post development, the brain
aintains structural and functional plasticity, which allows us to
earn, memorize and to adapt our behavior accordingly. Genetic
efects that compromise brain development, function, and plas-
icity can cause cognitive disorders such as intellectual disability
ID).
ID, previously referred to as mental retardation, is a collective
erm for a group of phenotypically and genetically heterogeneous
iseases that share impaired cognitive function as a common hall-
ark (van Bokhoven, 2011). ID is deﬁned by an IQ lower than
0, presenting with deﬁcits in adaptive behavior (e.g. self-care,
ocial and interpersonal skills) at an age of onset before 18 years
American Psychiatric Association, 1994). This deﬁnition distin-
uishes ID from late-onset neurodegenerative disorders. ID affects
s much as 2% of the population and, because of the high frequency
nd the need for lifelong care, the total health care expenditures far
xceed those of other mental handicaps (Ropers and Hamel, 2005).
D is thus a major unsolved medical and socioeconomic challenge
or society (Ropers, 2008).
ID is often distinguished into non-syndromic and syndromic
orms. In syndromic ID, patients present with clinical features in
ddition to ID, such as behavioral abnormalities, dysmorphisms,
nd metabolic defects. ID can also be classiﬁed by severity, ranging
rom mild (IQ 50–69) and moderate ID (IQ 35–49) to severe (IQ
0–34) and profound ID (IQ <20) (American Psychiatric Association,
994). Clinical and genetic aspects of ID have been extensively
eviewed elsewhere (Ellison et al., 2013; Mefford et al., 2012;
opers, 2008; van Bokhoven, 2011). To date, more than 600 genes
ave been identiﬁed that cause ID when mutated (our unpublished
iterature survey), yet the majority of ID genes still await discovery
van Bokhoven, 2011).
Because of the genetic heterogeneity, it has been a major chal-
enge to comprehensively investigate genetic causes of ID. The
ruit ﬂy Drosophila emerges as a very powerful organism for such
ndeavors. In this review, we aim to provide an overview on the
ontribution that Drosophila research has made to our understand-
ng of ID, and thus to the genetic control of cognition. We further
iscuss future challenges and current limitations in ID-related
debate how the lessons learnt from ID research in Drosophila can
be applied to other cognitive disorders with complex and poorly
understood genetics.
2. Advantages and applications of Drosophila as a model for
cognitive disorders
Understanding the function of the human brain is one of the
main challenges in neuroscience. Researchers have turned toward
organisms with more simple and easily manipulable brains to study
fundamental brain processes on a molecular, cellular and circuit
level. The Drosophila brain is, with approximately 100,000 neurons,
relatively small yet sufﬁciently complex to provide a suitable model
(Bellen et al., 2010). Despite the evolutionary distance between ﬂies
and humans, a strong conservation of genes, pathways and regu-
latory molecular networks has been demonstrated. 75% of human
disease genes have related sequences in Drosophila (Bier, 2005).
Correspondingly, we  found unambiguous counterparts for 73% of
ID genes in Drosophila (Oortveld et al., 2013).
In contrast to mammalian models, the generation of ﬂy mutants
is easy, cheap and fast. Moreover, the pool of publically available
stocks that can be readily utilized to induce gain- and loss-of-
function is enormous and steadily increasing (Bellen et al., 2010;
Dietzl et al., 2007; Matthews et al., 2005). Drosophila is well suited
for ID research, as it provides numerous approaches to investi-
gate defects in neuronal morphology and function along with the
possibility to assay cognitive processes. Below and in Fig. 1, we sum-
marize how Drosophila can be used as a model to better understand
the mechanisms underlying ID and other genetic disorders.
1. Gene function can be analyzed at a relatively high throughput
by gene manipulation, followed by characterization of the result-
ing molecular, cellular and/or behavioral phenotypes. Drosophila
mutant, knockdown, or overexpression strains can be ordered
from public stock centers, or new strains can be generated.
2. The primary origin of a phenotype can be determined by cell
type-speciﬁc gene manipulation, e.g. through the use of the UAS-
GAL4 system (Brand and Perrimon, 1993; Duffy, 2002). Large
collections of promoter elements and tools are available that can
be used to individually manipulate speciﬁc tissues, subsets of cell
populations, and even single cells.esearch, including identiﬁcation of molecular pathways that are
isrupted in ID, bottlenecks in diagnostics, and development of
herapeutic intervention. We specify how Drosophila can help to
rovide conceptually novel insights into these matters. Finally, we3. Temporal requirements for gene function can be determined
through manipulation with molecular switches that can ﬂexibly
be turned on or off. Such temporal information can be of crucial
importance for the prospects of therapeutic intervention.
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aig. 1. Advantages and application of Drosophila as a disease model. The numerous
ell  suited to increase fundamental knowledge and provide translational beneﬁts f
. Hypotheses can be tested in context of an intact organism. Such
hypotheses can include everything from the presumptive regu-
lation of one gene by another (e.g. using a molecular readout) to
the regulation of a speciﬁc behavior by a certain type of neuron
or neuronal circuit.
. Disease-relevant tissues can be acquired for analyses in unlim-
ited quantities. In brain research this is an important added
value, since the human brain can only be studied post-mortem
or with non-invasive imaging technology. The Drosophila brain
or neuronal subtypes can be studied by various molecular and
imaging techniques, down to subcellular resolution.
. Genetic modiﬁer screens can be used to isolate genes that genet-
ically interact with the disease gene of interest. Such modiﬁers
of ﬂy disease model phenotypes represent candidate genes or
risk factors for the same or related disease.
. The possibility to genetically combine two or more mutations
in different genes has made it possible to dissect molecular
networks, for example the hierarchy of signaling pathways.
. Finally, it is an excellent tool for testing large numbers of chem-
ical compounds for their ability to alleviate ﬂy phenotypes,
paving the way for therapeutic trials in mammalian models and
humans.
The fundamental knowledge that can be generated in this man-
er has great potential to ﬁnd its way into the clinic (Fig. 1). Taken
ogether, these features make Drosophila an extremely valuable
rganism to investigate human disease of the brain including ID.
. Drosophila models of ID
At the beginning of the new millennium, Drosophila was used
or the ﬁrst time to address ID gene function. Wan  et al. studied
mr1, the Drosophila ortholog of the Fragile X mental retardation
ene (Wan  et al., 2000). Drosophila has now been used for over a
ecade to model ID, which has provided a large amount of disease-
elevant information. In this chapter, we summarize some of these
nsights into ID gene function and pathology..1. The contribution of behavioral tests to study ID
One of the advantages of working with an animal model such
s Drosophila is that the effect of gene manipulation can be studiedaches to investigate defects in neuronal morphology and function make Drosophila
at the level of the whole organism. ID genes have been tested for
behavioral defects, starting from relatively simple and proceeding
to more complex behaviors. The role of some ID genes has been fur-
ther dissected and mapped to speciﬁc tissues or neuronal circuits.
A range of assays has been used to address simple ﬂy behavior,
including tracking of larval crawling and motor development, neg-
ative geotaxis, phototaxis, and ﬂight assays. These assays are robust,
relatively simple and quick to perform. Mutant ﬂies can be tested
for an effect on their general ﬁtness and, when combined with
cell-speciﬁc manipulation tools, for the requirement of a gene in
a tissue/cell-type of interest. For example, in a ﬂight assay Fmr1
mutant ﬂies display uncoordinated behavior, which has been com-
pared to delayed motor development that is seen in some patients
with Fragile X syndrome (Zhang et al., 2001). The Drosophila model
of Angelman syndrome, a Ube3a mutant strain, has poor climbing
ability indicative of motor dysfunction, resembling severe loss of
motor coordination in patients with Angelman syndrome (Wu  et al.,
2008). However, the degree and pattern of neuronal dysfunction
can differ between humans and Drosophila. For example, inacti-
vating mutations in Drosophila Nab2, the ortholog of the human
gene ZC3H14, cause defects in locomotion, whereas the patients are
reported to have a non-syndromic ID phenotype (Pak et al., 2011).
Drosophila also offers plenty of opportunities to test more
complex and cognitive behaviors, most importantly learning and
memory. Since ID patients suffer from several aspects of impaired
learning and memory capabilities (Bolduc and Tully, 2009), it is of
great interest to investigate the role of ID gene orthologs in these
processes. Indeed, the number of such studies has been increasing
rapidly within the past years. The most commonly used paradigms
were olfactory learning and courtship conditioning (Bolduc and
Tully, 2009), but also spatial learning and habituation paradigms
have been applied to ID models (see below). Learning and/or
memory defects have been found associated with mutations in
Drosophila orthologs of GNAS (Connolly et al., 1996), NF1 (Guo et al.,
2000), FLNA (Dubnau et al., 2003), RSK2 (Putz et al., 2004), FMR1
(McBride et al., 2005), PRSS12 (Didelot et al., 2006), UBE3A (Wu
et al., 2008), PQBP1 (Tamura et al., 2010), EHMT1 (Kramer et al.,
2011), NSUN2 (Abbasi-Moheb et al., 2012), ANK3 (Iqbal et al., 2013),
CEP89 (van Bon et al., 2013) and GATAD2B (Willemsen et al., 2013).
Most studies so far have only utilized a single paradigm to inves-
tigate learning and/or memory in a speciﬁc ID model, whereby the
choice of the assay was not based on the clinical phenotype or
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iology of the gene but rather determined by the expertise of the
nvestigating laboratory. It is interesting to note that some multi-
aradigm studies found distinct mutant phenotypes, depending on
he type of mutation and behavioral paradigm tested. For exam-
le, Drosophila S6kII mutants were tested in two  learning tasks:
perant place learning and Pavlovian olfactory conditioning (Putz
t al., 2004). The S6kII protein is part of the Ras extracellular signal-
egulated kinase (ERK) signaling pathway and the human ortholog
PS6KA3 is associated with Cofﬁn-Lowry syndrome. In three tested
6kII mutants, expression was reduced through a P-element inser-
ion, a partial, or a full gene deletion. The P-element insertion
utant only affected operant place learning. The partial deletion
utant, lacking part of the N-terminal kinase domain, performed
oorly in both learning tasks. The null mutant surprisingly only
ffected olfactory learning. These ﬁndings suggest that the type
f allele can determine the behavioral read-out, even when all
lleles presumably represent (partial) loss-of-function conditions.
his appears analogous to the human situation where extensive
linical variability is associated with allelic mutations. Work on
HMT mutant ﬂies, the Drosophila model of Kleefstra syndrome,
llustrates that the function of a gene also depends on the behav-
oral context. EHMT mutants show defects in habituation, a form
f non-associative learning, whereas learning in the courtship con-
itioning paradigm is unaffected (Kramer et al., 2011). Differences
etween paradigms have also been found in classic learning and
emory mutants (for a review see e.g. (Engel and Wu,  2009)) and
ay  depend on expression patterns of the gene, architecture of
he behavior-underlying circuit or different neuronal properties.
his makes it difﬁcult to impossible, with current knowledge, to
ationalize which paradigm to preferably use when modeling ID.
The combination of cognitive tests and genetic approaches in
rosophila can be used to distinguish between genes that execute
 speciﬁc neuronal function in cognitive processes and genes that
ct elsewhere, causing ID in an indirect manner. This is of partic-
lar interest when ID patients present with a broader spectrum of
linical features, like Kleefstra syndrome where ID patients present
ith developmental delay, hypotonia, distinct facial and other fea-
ures (Willemsen et al., 2012). Transgenic re-expression of EHMT in
ll neurons (‘pan-neuronally’) rescued courtship memory defects in
HMT mutant ﬂies, indicating a direct role of EHMT in cognitive pro-
esses (Kramer et al., 2011). Very similarly, the autosomal-recessive
D gene Nsun2,  associated with microcephaly and additional clin-
cal features, was shown to be essential for short-term memory
n the aversive olfactory conditioning paradigm. The phenotype
as rescued by pan-neuronal re-expression of Nsun2 in the mutant
ackground (Abbasi-Moheb et al., 2012).
The same and other conditional strategies, often exploiting the
AS-GAL4 system, can be applied to identify the subset of neu-
ons that are important for speciﬁc behaviors (Fig. 1). A brain
tructure called the mushroom body is known to be required
or several forms of learning and memory in Drosophila. Re-
xpression of EHMT in mushroom body neurons was  sufﬁcient
o rescue courtship memory defects shown by EHMT mutants
Kramer et al., 2011). Mutant ﬂies of the neurotrypsin-related
ene Tequila display defective long-term memory in the olfac-
ory learning paradigm (Didelot et al., 2006). RNAi-mediated
nockdown of Tequila in mushroom body neurons was  suf-
cient to cause the defects. Likewise, Wah, the ortholog of
ANSL1, and simj, the ortholog of GATAD2B, were investigated.
ushroom body-speciﬁc knockdown of wah reduces learning abil-
ty in courtship conditioning and pan-neuronal knockdown of
imj decreases light-off jump reﬂex habituation (non-associative
earning) (Koolen et al., 2012; Willemsen et al., 2013). In addi-
ion, 10 out of 37 Drosophila orthologs of recently identiﬁed ID
andidate genes (Najmabadi et al., 2011) are necessary for nor-
al  long-term memory in courtship conditioning, as found byehavioral Reviews 46 (2014) 326–342 329
pan-neuronal RNAi experiments (K. Keleman, personal communi-
cation).
In summary, learning and memory function is affected in a sig-
niﬁcant number of ID models. Such ﬁndings and models provide
additional evidence for the role of the investigated genes in cog-
nitive processes, and allow for further dissection of the underlying
molecular and cellular defects.
3.2. Neuronal development and architecture
Drosophila offers many opportunities to study the role of genes
in the organization of the brain and its nervous system in greater
detail. Here we  provide an overview on how structural information
on synapses, dendrites and axons helps to further understand the
cellular basis of ID.
A signiﬁcant number of ID genes encode proteins involved in
synapse biology (van Bokhoven, 2011). Because of this observation
and since synaptic morphology and function is important for cogni-
tive processes, many studies put emphasis on determining the role
of ID genes at a Drosophila synapse. The Drosophila neuromuscular
junction (NMJ) has been widely used to address questions related to
mechanisms underlying neurotransmitter release, synapse forma-
tion and physiology (Ruiz-Canada and Budnik, 2006a). Like many
central excitatory mammalian synapses, the Drosophila NMJ  is
glutamatergic, contains similar molecular components and is reg-
ulated by orthologous pathways. The synaptic terminals of the
NMJ  are organized in boutons and each bouton contains numer-
ous presynaptic release sites, known as active zones. Zhang et al.
showed that loss of FMR1 causes synaptic overgrowth, whereas
overexpression causes undergrowth, with fewer (but larger) synap-
tic boutons (Zhang et al., 2001). Based on phenotypic similarities, a
functional link between Fmr1 and futsch, a microtubule-associated
protein, was  hypothesized and conﬁrmed by a double mutant con-
dition that reversed the Fmr1 mutant overgrowth phenotype. The
importance of the microtubule network in NMJ  development and
function was further underscored by a study that investigated the
tubulin-speciﬁc chaperone E gene (TBCE), which is linked to the
congenital hypoparathyroidism-retardation-dysmorphism (HRD)
syndrome (Jin et al., 2009). Drosophila tbce was found to func-
tion both pre- and postsynaptically. Knockdown at either side
of the NMJ  caused an increase in the number of branches and
boutons, whereas the bouton area was smaller. This observation
corresponds with the hypothesis that synaptic growth depends on
microtubule dynamics, but not necessarily on the absolute quantity
of microtubules (Ruiz-Canada and Budnik, 2006b). In addition to
microtubule-related ID genes, NMJ  structural abnormalities have
recently been described in ID ﬂy models of mitochondria-related
proteins, such as Cep89 and its Drosophila ortholog CG8214 (van
Bon et al., 2013), UbcD6 and its Drosophila ortholog Rad6a (Haddad
et al., 2013), adhesion molecules like the Neurexins (Zweier et al.,
2009), intracellular phospholipases (Schuurs-Hoeijmakers et al.,
2012) and proteins involved in chromatin remodeling, like KANSL1
and GATAD2B and their Drosophila orthologs wah  (Koolen et al.,
2012) and simj (Willemsen et al., 2013), respectively.
Beyond morphological analyses, the NMJ  is a suitable model
to directly measure the effect of mutations on neurotransmis-
sion. Larval muscles and motor nerves are relatively large; this
genetically traceable synapse is therefore fully amenable to elec-
trophysiological analyses. For example, the combination of pre-
versus postsynaptic manipulation and electrophysiology revealed
that tbce is exclusively required presynaptically for normal neu-
rotransmission. Altered levels of presynaptic tbce results in an
increase in the excitatory junction potential (EJP) and miniature
EJP (mEJP) amplitudes, whereas postsynaptic manipulation does
not change these parameters (Jin et al., 2009). In a large-scale
screen focused on postsynaptic glutamate receptor localization,
3 d Biob
m
c
i
w
d
t
s
e
g
l
p
e
t
(
N
r
e
g
t
p
t
m
p
(
v
t
e
l
l
s
f
t
s
n
p
t
v
h
e
I
t
r
w
D
n
ﬂ
o
w
F
a
a
b
t
2
r
2
i
e
m
d
r
p
230 M. van der Voet et al. / Neuroscience an
utations in rt, the Drosophila ortholog of POMT1,  were found to
ause a reduced level of GluRIIB (Wairkar et al., 2008). Mutations
n POMT1 are linked to muscular dystrophy-dystroglycanopathies
ith ID (van Reeuwijk et al., 2006). Drosophila rt synapses show
ecreased synaptic strength and release probability but no struc-
ural NMJ  defects. These defects were only rescued when rt was
imultaneously re-expressed pre- and postsynaptically (Wairkar
t al., 2008). Moreover, it was demonstrated that rt is required to
lycosylate the Drosophila dystroglycan ortholog Dg in vivo, which
ikely is essential for proper synapse function.
The giant ﬁber system (GFS) has been used to study mor-
hology and function of central synapses. The GFS mediates the
scape response of adult ﬂies and connects with the dorsal longi-
udinal motoneurons and the Tergo Trochanteral Muscle neuron
TTMn). This system was used to study the role of Drosophila
rg, whose ortholog L1CAM is associated to a variety of neu-
ological diseases, in central synapse formation (Godenschwege
t al., 2006). Whereas Nrg null mutants displayed severe axon
uidance defects that precluded synaptic analyses, ﬂies with
he homozygous missense mutation Nrg849, located at a similar
osition as one of the many identiﬁed human pathological muta-
ions, showed such defects only with low penetrance. The Nrg849
utants were characterized by structurally and functionally com-
romised synaptic connections between GFS and TTMn neurons
Godenschwege et al., 2006; Hortsch et al., 2009). Expression of
ertebrate L1CAM simultaneously at both the pre- and postsynap-
ic site was able to rescue these synaptic defects (Godenschwege
t al., 2006).
The Drosophila central synapse of the VS1 neuron of the
obula plate vertical system was recently found to be regu-
ated by the Fragile X protein Fmr1. The VS1 neuron shows
mall actin-enriched protrusions that are morphologically and
unctionally similar to dendritic spines, mammalian postsynap-
ic compartments, making this synapse an attractive postsynaptic
ystem to study in ID models. In wild-type ﬂies, VS1 spine
umber and length increase after sleep deprivation and show
runing when ﬂies are allowed to sleep. FMR1 is required for
his sleep-dependent synaptic renormalization. This study pro-
ided compelling structural evidence for sleep regulating synaptic
omeostasis and for involvement of an ID gene therein (Bushey
t al., 2011).
Changes in dendritic arborization are commonly observed in
D patients (Kaufmann and Moser, 2000) and might contribute to
heir cognitive impairment. The dendritic arborization (DA) neu-
ons in Drosophila,  also named multiple dendritic neurons, are a
ell-suited model to study dendrite architecture and arborization.
A neurons, particularly the morphologically complex class IV DA
eurons (Jan and Jan, 2010), have been examined in a handful of
y models of ID genes. Fmr1 mutants show an elevated number
f higher-order dendritic branches, reintroducing one copy of the
ild-type Fmr1 gene reversed the phenotype. Overexpression of
mr1 has the opposite effect, revealing a dosage-dependent mech-
nism (Lee et al., 2003). Loss of Ube3a or EHMT in the Angelman
nd Kleefstra syndrome ﬂy models results in reduced dendritic
ranching, which suggests that a dendritic pathology might con-
ribute to the human phenotypes (Kramer and van Bokhoven,
009; Lu et al., 2009). More recently dendrite defects were also
eported in the Ube3a and Ehmt1 mouse models (Balemans et al.,
013; Miao et al., 2013). The importance of dendrite morphology
n the etiology of ID was also applied to strengthen the hypoth-
sis that haploinsufﬁciency of the CDK19 gene causes ID with
icrocephaly and congenital retinal folds in a single patient. Knock-
own of the CDK19 Drosophila ortholog Cdk8 in DA neurons causes
educed dendritic ﬁelds and reduced dendritic complexity, sup-
orting the link of CDK19 to the ID phenotype (Mukhopadhyay et al.,
010).ehavioral Reviews 46 (2014) 326–342
Outgrowing axons follow a precise path during development
to connect to other neurons via their terminal synapses. Connec-
tions must be made with the correct targets, which is challenging
considering the distance and large number of pathﬁnding choices.
It is likely that axonal biology, like other aspects of neuronal
morphology, plays an important role in the etiology of ID. White
matter tracts in the human brain, rich in myelinated axons, can
be visualized using diffusion tensor imaging (Huang and Vasung,
2013). However, due to technical limitations, including lack of a
method analogous to dendritic Golgi staining that would allow
tracing of single axons, this ﬁeld in humans remains largely unex-
plored. Drosophila can be used to study the processes of axon
growth, pathﬁnding and branching by labeling subsets or single
axons. Work on the Drosophila Fragile X model played a pioneer-
ing role linking Fmr1 to these processes. Loss of Fmr1 strongly
affects neurite extension and axon guidance of both dorsal clus-
ter and lateral neurons, but not photoreceptor neurons (Morales
et al., 2002). Ectopic axon branching patterns and axon over-
growth have also been observed in neurons of the mushroom
body (Michel et al., 2004; Pan et al., 2004). In mutant Fmr1 mush-
room body  neurons, these phenotypes have been shown to
result from defects in activity-dependent axon pruning (Tessier and
Broadie, 2008). Evidence for axonal functions of the Fragile X pro-
tein also accumulates in mammalian systems (Section 4.2). It is to
be hoped that further progress in human brain imaging techniques
in combination with functional data coming from model organ-
isms will shed more light on the contribution of axonal biology on
ID.
3.3. ID gene function and circadian rhythm
Apart from defects in the above-discussed aspects of neuronal
development and function that are common to at least some ID
models, work in Drosophila linked ID gene function to circadian
rhythm. Fmr1 mutant ﬂies are arrhythmic, with an erratic pat-
tern of locomotor activity including periods of hyperactivity, and
defects in circadian period upon overexpression (Dockendorff et al.,
2002; Inoue et al., 2002; Morales et al., 2002). Fmr1 was  shown to
be required for normal cAMP response element-binding protein
(CREB) activity, downstream of clock neurons (Dockendorff et al.,
2002). Subsequently, circadian rhythm defects were also found
for the mammalian Fragile X protein family (in Fmr1/Fxr2 double
mutant mice, hetero- and homozygotes) (Zhang et al., 2008). Alter-
ations in the circadian rhythm are also increasingly considered as
a cause rather than a consequence of neuropsychiatric disorders
(Menet and Rosbash, 2011). Given the observed sleep disorders
in Fragile X patients and the overlap of ID with neuropsychiatric
disorders (further discussed in chapter 7) alterations in circadian
rhythms might contribute to behavioral alterations in ID patients
(Zhang et al., 2008). Circadian rhythm defects in other ID models
such as Ube3a mutant ﬂies (Wu  et al., 2008) further support this
idea.
3.4. Defective RNAi machinery and ID
Drosophila work on Fragile X syndrome pioneered the link
between the RNAi machinery and human disease. Two back-to-
back papers published in 2002 discovered an association between
Fmr1 and the RNA-induced silencing complex (RISC), and the RNase
III enzyme Dicer, implicating Fmr1 as part of the RNAi-related appa-
ratus (Caudy et al., 2002; Ishizuka et al., 2002). Similarly, Dicer
and eIF2C2, the mammalian ortholog of Argonaute-1 (AGO1), were
also found to interact with mammalian FMRP (Jin et al., 2004).
The identiﬁcation of biochemical and genetic interactions of the
Fragile X protein with components of the miRNA pathway, the
d Biobehavioral Reviews 46 (2014) 326–342 331
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Dystroglycanopathies
X-linked Alpha-Thalassemia/
mental retardation syndrome
Fig. 2. Thirteen years of publications for Drosophila models of intellectual disability.
Thirteen years of Drosophila as a model to study intellectual disability (2000–June
2013) yielded 114 publications, from which more than half (n = 63) describe Fragile
X  syndrome, the most extensively studied ID disorder. Other frequently inves-M. van der Voet et al. / Neuroscience an
atter demonstrated in Drosophila,  could point to a mechanism
hrough which the protein exerts its function (Jin et al., 2004).
.5. Contributions of fundamental biological studies
Many studies of Drosophila ID gene orthologs have been per-
ormed without the explicit intent to investigate their associated
isease. Examples of ‘incidental ID models’ include studies where
isease gene orthologs were found in unbiased screens to cause
euronal phenotypes. Such screens have provided unexpected
nsights into ID, such as the discovery of a post-mitotic role for
ubunits of the cohesin complex, well known for their role in
ister-chromatic cohesion during meiosis and mitosis (Schuldiner
t al., 2008). The cohesin complex subunits NIPBL, SMC1A,  SMC3
nd RAD21 are mutated in Cornelia de Lange syndrome (CdLS).
rosophila studies revealed a function in axon pruning in the mush-
oom body and dendrite targeting in olfactory projection neurons.
his post-mitotic role of cohesin was found to be mediated through
ltered gene expression (Pauli et al., 2008; Schuldiner et al., 2008).
n addition, a mosaic screen in the Drosophila wing epithelium has
ncovered a role for SMC3 in planar cell polarity (PCP) an important
rocess in development and function of the nervous system (Mouri
t al., 2012; Tissir and Gofﬁnet, 2013).
Incidental ID models also arise when genes have been inves-
igated in Drosophila prior to disease implication. The Drosophila
inibrain (mnb) kinase was reported in 1984 to have a critical
ole in Drosophila brain development. mnb  mutants have a reduced
rain volume of 40–50% compared to controls, with a drastic reduc-
ion in cell numbers (Fischbach and Heisenberg, 1984). It was
ot until 24 years later that de novo truncations in the human
nb ortholog DYRK1A were identiﬁed in unrelated patients with
 clinical phenotype including a signiﬁcantly reduced brain size
microcephaly) (Møller et al., 2008). Another example is the class
 helix-loop-helix transcription factor daughterless (da) that con-
rols expression of important neuronal genes and is required for
eural differentiation in Drosophila.  The association to disease came
o light 19 years later when mutations in the human ortholog TCF4
ere found to cause Pitt-Hopkins syndrome (PTHS), a severe ID
isorder (Amiel et al., 2007; Brockschmidt et al., 2007; Caudy et al.,
988; Zweier et al., 2009). Drosophila Ankyrin-2,  the ﬂy ortholog of
uman ANK2 and ANK3, was found to be required for synapse sta-
ility in genetic screens. Mutants show synaptic disassembly and
etraction and disrupted neuronal excitability (Koch et al., 2008;
ielage et al., 2008). Recently, mutations in ANK3 were identiﬁed
n patients with ID and the cognitive defects in humans were sup-
orted by memory defects in Drosophila (Iqbal et al., 2013). These
ndings highlight the importance and direct relevance of funda-
ental studies in Drosophila to human disease.
.6. Concluding remarks
The Fragile X mental retardation gene was the ﬁrst ID gene to be
tudied in Drosophila,  and to date still is the most frequently studied
Fig. 2). Phenotypes that have been found in the Fragile X ﬂy have
uided research on other Drosophila ID models, such as ﬂy models
f the X-linked Alpha thalassemia/mental retardation syndrome
ATRX) and genes involved in dystroglycanopathies (Fig. 2) (Fradkin
t al., 2008; Lee et al., 2007; Marrone et al., 2011; Wairkar et al.,
008; Zhan et al., 2010) and many others as discussed above. This
hapter provided an overview on how Drosophila has been used as
 model to study ID. How Drosophila can be exploited as a model
or ID in future fundamental and translational research is discussed
elow.tigated syndromes are X-linked alpha-thalassemia/mental retardation syndrome
(n  = 5), Dystroglycanopathies (n = 4) and Rett syndrome (n = 4). The around 30 other
ID  disorders are represented by less than four publications per disorder.
4. Molecular pathways and functional modules in cognitive
(dys)function
4.1. ID genes – different pieces of the same puzzle
Perhaps one of the most important and exciting outcomes of
ID research is the accumulating evidence that ID genes encode
proteins that operate together in common complexes, pathways
or networks. Diverse cellular functions and mechanisms have
emerged, including intracellular signal transduction pathways that
regulate presynaptic pathways, postsynaptic protein complexes,
cytoskeleton dynamics, epigenetic modulation of chromatin struc-
ture, and transcription (van Bokhoven, 2011).
The pathways most prominently affected by proteins implicated
in ID are Rho and Ras small GTPase signaling cascades. Rho GTPases
are key regulators of actin remodeling. The regulation of the actin
cytoskeleton is important for many aspects of neuronal morphol-
ogy and function, including remodeling and plasticity of actin-rich
dendritic spines. Dendritic spine plasticity is known to correlate
with learning and memory, and abnormal dendritic spines are a
common feature of ID (Kaufmann and Moser, 2000; Lamprecht and
LeDoux, 2004). ID genes/proteins operating in Rho GTPase path-
ways belong to the classes of Rho GTPase activating proteins (GAPs:
PHN1, SRGAP3/MEGAP, OCRL1),  Rho guanine nucleotide exchange
factors (GEFs: ARHGEF6, ARHGEF9, and FGD1) and Rho GTPase effec-
tor proteins (PAK3) (Dierssen and Ramakers, 2006; Nadif Kasri and
Van Aelst, 2008; Schenck et al., 2004).
The Ras/MAPK pathway is part of cellular signaling cascades
and has pleiotropic functions at the pre- and postsynaptic site.
Presynaptically Ras/MAPK regulates neurotransmitter release at
the axon terminal and depending on the type of neuron, excitatory
or inhibitory, a similar mutation can have opposite downstream
effects. Postsynaptically the Ras/MAPK pathway functions as a
signal integrator at the dendritic spines, where it regulates tran-
scription and translation events (Thomas and Huganir, 2004). The
transcription regulation through transcription factor CREB is essen-
tial for many forms of learning and memory (Lonze and Ginty,
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002). Genes that are mutated in ID are the Ras GTPases (HRAS
nd KRAS), downstream effectors of Ras (RAF1, BRAF, MEK1,  MEK2,
nd RPS6KA3/RSK2) and regulators of the Ras/MAPK pathway (SHP2,
OS1, NF1,  SPRED1, SHOC). The clinically overlapping disorders are
ommonly referred to as Rasopathies (Krab et al., 2008b).
Additional pathways in ID have emerged. Among the more than
0 ID genes that encode chromatin remodeling factors are sev-
ral that physically interact and/or functionally cooperate (van
okhoven, 2011). MECP2 for example, the methyl-CpG-binding
rotein mutated in Rett syndrome, has been found in complexes
ith ATRX/XNP, DNMT3B, CREBBP, RPS6KA1/RSK, and CDKL5
Kramer and van Bokhoven, 2009).
The examples listed above show that identifying these path-
ays greatly improves our knowledge of involved mechanisms,
ontributing to our understanding of the patient phenotype. How-
ver, the so far emerging pathways are among the best-investigated
ellular signaling pathways. It will be more challenging to unravel
he role of less investigated or unknown pathways underlying ID.
his will be further discussed in the next section.
.2. Drosophila to deﬁne molecular pathways and networks
nderlying ID
One of the most successful applications of classic Drosophila
enetics is modiﬁer screens. The aim of modiﬁer screens is to iden-
ify second site mutations that modify a phenotype caused by a gene
f interest. Such unbiased screens can reveal functionally related
enes, and thereby additional components of a pathway. A seminal
xample is the above-mentioned Ras/MAPK pathway, which was
escribed and dissected in the context of Drosophila eye develop-
ent (Karim et al., 1996; Therrien et al., 2000). The same principle
an also be utilized in a targeted manner to test for genetic inter-
ctions between potentially connected genes.
Loss of the Fragile X protein causes altered synapse morphol-
gy in human patients, mice and Drosophila models (Zarnescu
t al., 2005). Research in Drosophila revealed that the Fragile X
rotein, via the Rac1 effector protein CYFIP/Sra-1, is linked to
ctin-remodeling Rho GTPase pathways (Schenck et al., 2003). It
as shown that CYFIP/Sra-1 acts as a Rac1 effector that antago-
izes Fmr1 function at the Drosophila NMJ. This study provided the
rst link between signal-dependent cytoskeleton remodeling and
ragile X syndrome, raising the interesting possibility that actin
emodeling and local protein synthesis at synapses, two  crucial
rocesses in synaptic plasticity, are directly co-regulated (Schenck
t al., 2003). Further connections between the Fragile X protein and
ore players of actin remodeling pathways have been subsequently
evealed. Expression of Drosophila Rac1 and proﬁlin were found
o be controlled by Fmr1, and further ﬁndings in mammalian sys-
ems placed additional emphasis on defects in actin misregulation
s a major problem in Fragile X syndrome and its neuropathology
Castets et al., 2005; Chen et al., 2010; Lee et al., 2003; Reeve et al.,
005)
Another link was recently described between the Fragile X pro-
ein and the Down syndrome cell-adhesion molecule (Dscam).
SCAM is upregulated in Down syndrome and believed to con-
ribute to the neuronal pathology of Trisomy 21 (Alves-Sampaio
t al., 2010; Rachidi and Lopes, 2007). The protein is involved in
ntraneuronal self-recognition, axon guidance and synaptic target
election (Hattori et al., 2008). Drosophila was used as a model to
tudy the mechanisms via which Dscam exerts these conserved
unctions. Following up on earlier ﬁndings that identiﬁed Dscam
s an RNA target of Fmr1, the authors found that Fmr1 sup-
resses Dscam translation to restrict presynaptic arbor growth in
 dose-dependent manner (Brown et al., 2001; Darnell et al., 2011;
im et al., 2013a). This is in agreement with a second study that
eported that increased Dscam protein levels, either by Dscamehavioral Reviews 46 (2014) 326–342
overexpression or by reduced Fmr1 levels, results in axonal target-
ing errors in pSc mechanosensory neurons (Cvetkovska et al., 2013).
Moreover, reducing Dscam levels in Fmr1 null ﬂies reduces synaptic
targeting errors and rescues behavioral defects. Excess Dscam pro-
tein may  thus be a common molecular mechanism that underlies
altered neural wiring in both disorders (Cvetkovska et al., 2013).
These studies added to an increasing body of evidence that Fmr1,
in addition to its dendritic and postsynaptic functions, plays impor-
tant roles presynaptically and in axons (Contractor, 2013; Patel
et al., 2013).
Shared ID-associated clinical phenotypes, if sufﬁciently charac-
teristic, can generate important novel hypotheses with respect to
proteins that functionally cooperate. Such hypotheses are testable
in Drosophila.  To date, mutations in three genes have been shown to
cause Pitt-Hopkins syndrome (PTHS) and phenotypically overlap-
ping disorders. These genes encode the transcription factor TCF4,
the presynaptic adhesion protein NRXN1, and the distal neurexin-
family member CNTNAP2 (Zweier et al., 2009, 2007). Whereas
the involvement of NRXN1 suggests that PTHS is a synaptopa-
thy, CNTNAP2 organizes nodal microdomains of myelinated axons
and evidence for a synaptic role of the encoded protein has been
lacking. Using Drosophila as a model, it was shown that overex-
pression of either protein, Neurexin-1 ortholog (Nrx-1) or CNTNAP2
ortholog (Nrx-IV), reorganizes synaptic (NMJ) morphology and
induces increased density of active zones, the synaptic domains of
neurotransmitter release. Moreover, dosage of either protein deter-
mines the level of the presynaptic active zone protein bruchpilot,
indicating a possible common molecular mechanism in Nrx-1 and
Nrx-IV mutant conditions. These ﬁndings and the observation of
anti-Nrx-IV immunoreactivity at the investigated synapse argue
that a shared synaptic mechanism contributes to the similar clin-
ical phenotypes in NRXN1 and CNTNAP2 patients (Zweier et al.,
2009). Novel roles for CNTNAP2, including a function in synapse
organization, have subsequently also been reported in mammalian
neurons (Anderson et al., 2012). Of note, the phenotypic commonal-
ities caused by mutations in NRXN1 and CNTNAP2 extends beyond
PTHS. Milder conditions (heterozygous variants or copy-number
variations) have been implicated in an overlapping multitude of
neuropsychiatric disorders, including Autism Spectrum Disorder
(ASD) and Schizophrenia (Zweier et al., 2009). This also matches
the role of TCF4, which in a recent cross-disorder analysis by the
Psychiatric Genomics Consortium, has also been associated to ASD
and Schizophrenia (Psychiatric Genomics Consortium et al., 2013).
Interestingly, it has been recently shown that TCF4 can transacti-
vate the NRXN1  ˇ and CNTNAP2 promoters, suggesting that these
genes are under direct control of TCF4 (Forrest et al., 2012). The
molecular mechanisms that link the three PTHS genes and the
question in how far defects in neuronal differentiation versus
post-mitotic neuronal function contribute to ID in PTHS patients
warrants further investigation. The latter has important conse-
quences for therapeutic intervention strategies (see also chapter 6).
Drosophila has also been successfully applied to extend the
above-mentioned MECP2 functional network (see section 4.1),
even though MECP2 itself is not conserved in Drosophila.  Genetic
interaction experiments in transgenic ﬂies expressing human
MECP2 reveal that reduced dosage of osa is capable of suppress-
ing dendritic defects caused by altered MECP2 levels (Vonhoff et al.,
2012). Osa is the common Drosophila ancestor of human ARID1A and
ARID1B genes, subunits of the SWI/SNF complex that have recently
been shown to cause Cofﬁn-Siris syndrome (Santen et al., 2012;
Tsurusaki et al., 2012). Mutations in ARID1B have also been reported
as a frequent cause of moderate to severe ID with additional clin-
ical features and have been implicated in ASD (Hoyer et al., 2012;
O’Roak et al., 2012). Among the other identiﬁed modiﬁers of MECP2
is pbl,  a target of Ube3a, involved in Angelman syndrome as dis-
cussed above (Cukier et al., 2008). Rett and Angelman syndromes
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re both devastating neurological disorders that share, in addition
o ID, a number of other clinical features, suggesting a possible
echanistic overlap. Indeed, reduced Ube3a levels are able to sup-
ress a MECP2 gain-of-function eye phenotype, MECP2 and Ube3a
roteins physically interact and regulate the expression of shared
arget genes (Kim et al., 2013b). Thus, Drosophila studies have estab-
ished connections between MECP2 and other ID genes.
.3. Addressing other signatures common to (subsets of) ID
isorders
Identifying molecular mechanisms that are shared by ID disor-
ers could provide highly valuable information in several aspects:
1) for our fundamental understanding of the biology underly-
ng ID, (2) as biomarkers with potential applications in future
iagnostics, and (3) to deﬁne common targets for future thera-
eutic intervention. Such common mechanisms do not necessarily
eed to represent signaling pathways in which ID gene products
irectly operate. Shared transcriptional or metabolic dysregulation
nd other molecular ‘signatures’ can be important as well, even
f indirectly caused. First reported examples of such signatures
nclude altered immediate early gene expression through mutated
D genes MED23, MED12 or ERCC2/XPD (Hashimoto et al., 2011), and
ecreased tryptophan levels in ASD patients with and without ID
Boccuto et al., 2013).
It can be expected that future studies will report other defects
hat may  commonly occur in subsets of ID and/or other cognitive
isorders. Drosophila models make a suitable and rather unlim-
ted “test cohort” to comprehensively replicate and validate such
ndings, e.g. through biochemical approaches and metabolic mea-
urements in a large number of ID models. Drosophila experiments
an also provide direct evidence for the contribution of identiﬁed
ignatures to a relevant phenotype.
.4. Large-scale studies to identify novel ID networks and their
unction
Drosophila is well suited to generate large comparative pheno-
ypic datasets, because of the relative ease in which forward and
everse genetic screens can be performed. In vivo screening pro-
ides additional beneﬁts over cell-based models, because complex
henotypes such as cognition can be assayed.
Screens can be used to identify missing components in speciﬁc
rocesses or pathways, but they can also be used to obtain a broad
verview on function of a deﬁned group of insufﬁciently char-
cterized genes. Performing large-scale reverse genetic screens,
n combination with extensive phenotyping, could provide an
verview of the role of ID genes within the nervous system. In
ddition, performing large-scale phenotyping analyses in model
rganisms, compared to human patients, has several beneﬁts. First,
any of the conditions are rare, thus the small amount of patients
hat can be investigated is limiting. Second, patients are usually
een by different clinicians across various countries, which might
esult in inconsistent clinical analysis between patients. Third, one
annot control for genetic background and environmental fac-
ors in patients, whereas in model organisms such as Drosophila
he genetic background can be selected, and ﬂies can be raised
nder controlled conditions. Combined, this keeps the inﬂuence
f variants other than the gene in question to a minimum. Thus,
omparative phenotyping approaches in model organisms should
e able to signiﬁcantly contribute to the identiﬁcation of evolution-
rily conserved genotype-phenotype correlations that are relevant
o human disorders.
Based on the widely recognized principle that identical or
imilar phenotypes arise from disruptions of common processes,
omparative phenotyping approaches should be able to predictehavioral Reviews 46 (2014) 326–342 333
novel gene functions and map  previously unappreciated functional
modules and pathways. A recent study reported an RNAi-based
candidate screen, targeting genes involved in a range of neurolog-
ical disorders, for defects in synaptic and mitochondrial function.
Loss of UbcD6,  the Drosophila ortholog of ID gene UBE2A,  induces
a number of phenotypes that, unexpectedly for its established role
in the nucleus, resembles defects found in Parkin mutants (Haddad
et al., 2013). This phenotypic resemblance is due to an overlap
in function: Drosophila UbcD6 has been demonstrated to act as
an E2 ubiquitin-conjugating enzyme that, in combination with
an E3 ubiquitin ligase such as Parkin, ubiquitinates mitochondrial
proteins to facilitate the clearance of dysfunctional mitochondria,
preventing neuronal dysfunction (Haddad et al., 2013). A sec-
ond study systematically targeted 270 ID gene orthologs in the
Drosophila eye (Oortveld et al., 2013). Assessment of neuronal
function in behavioral and electrophysiological assays and multi-
parametric morphological analysis assigned many novel functions
to ID genes, including a requirement in basal neurotransmission
for 16 ID genes that had not previously been implicated in this
process in any system or organism. Grouping genes by their pheno-
types identiﬁed 26 highly connected functionally coherent modules
that comprise a total of 100 ID genes and successfully predict addi-
tional gene functions such as a role in synapse/NMJ development.
Interestingly, Drosophila phenotype groups show, in addition to ID,
signiﬁcant phenotypic similarity also in humans, indicating that the
identiﬁed functional modules are conserved. This study provides a
ﬁrst overview of the modular architecture of ID and has presented
unbiased evidence for a long suspected broad functional coherence
underlying ID.
The indicated two studies pose the question whether RNAi is
an appropriate tool to model ID disorders. Whereas loss- versus
gain-of-function approaches in targeted studies should always be
tailored to the clinical condition of interest, an inventory reported
by Oortveld et al. revealed that for the vast majority of ID genes
(partial) loss-of-function is thought to be the causative mechanism
(Oortveld et al., 2013). This supports RNAi approaches as a suitable
approximation to the large group of human ID disorders. Future
systematic screens will address ID gene function in further disease-
relevant contexts.
5. Clinical application of Drosophila I: gene identiﬁcation
and diagnostics
Drosophila has been used to identify genetic interactors of dis-
ease genes. Such research frequently aims to deliver candidate
genes that can either modify the human disease phenotypes or
directly cause (the same or a similar) disease. While this approach
will remain valid, the need for candidate genes has become
obsolete. With the advent of next-generation sequencing, human
genetics generates more candidates than at present can be inter-
preted. Here, we  anticipate an increasing contribution of Drosophila
to the interpretation of genetic variants and their pathogenicity.
5.1. Challenges in gene identiﬁcation in the era of
next-generation sequencing
The advent of next-generation sequencing technology, which
allows interrogation of unlimited amounts of genomic informa-
tion with base-pair precise resolution, has begun to revolutionize
human genetics. A number of ID syndromes were among the ﬁrst
diseases genetically solved by applying this technology after exome
capture, including Schinzel-Giedion syndrome (SETBP1), Kabuki
syndrome (KMT2D), and Baraitser-Winter syndrome (ACTB and
ACTG1) (Hoischen et al., 2010; Ng et al., 2010a; Riviere et al.,
2012). Common to these three and further successful studies is that
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equencing has been performed in a carefully selected, phenotyp-
cally coherent cohort of patients. This strategy strongly increases
he chances of ﬁnding the same gene to be affected in multiple
atients, thereby validating its causative nature. However, this
trategy cannot – or only to a minor extent – be applied to very rare,
henotypically heterogeneous or even non-syndromic ID cohorts.
n many cases, suspicious variants are observed only in single
atients or families (de Ligt et al., 2012; Najmabadi et al., 2011;
issers et al., 2010). Furthermore, even considering only de novo
utations, multiple potential disease-causing variants can be iden-
iﬁed within a single patient. The primary challenge in such studies
as shifted from data analysis to interpretation, so as to distinguish
etween background variants and pathogenic mutations. Currently
pplied ﬁlters that identify potential causal variants among all vari-
nts detected are based on variant frequency, conservation scores,
redicted deleteriousness to protein structure, and if available,
valuation of functional data of the affected gene (Ng et al., 2010b).
urveys carried out on copy-number variations have demonstrated,
nsurprisingly for biologists, that functional information collected
n model organisms is particularly powerful (Hehir-Kwa et al.,
010; Webber et al., 2009). The required functional data is available
owever for only a minority of genes, such as non-systematically
cquired information on 5000 mouse genes. This limitation holds
articularly true if only considering information relevant to the
isease-relevant tissue(s), such as the nervous system for ID dis-
rders. The paucity of relevant functional data has become a major
ottleneck for the interpretation of variants in research and in rou-
ine diagnostics.
.2. Guiding human genetics and clinical decision-making
hrough functional studies in Drosophila
Next-generation sequencing technology has already reached
iagnostics and in the following years is expected to become a
tandard in medical genomics (Gonzaga-Jauregui et al., 2012). The
eed for functional investigation of disease genes and variants can
afely be assumed to explode, at least (but probably not only) in
ases where human genetics/genomics will fail to detect recurrent
hanges.
Can animal models contribute to routine diagnostics? We
elieve so, but to overcome the bottleneck of lacking functional
ata, extraordinarily efﬁcient model organisms are required that
ermit the generation of relevant information in a short time and
n demand.
.2.1. Support for causality through disease-relevant gene
unction
Drosophila is in an excellent position to lend ad hoc support
o the causative nature of identiﬁed ID gene candidates that are
dentiﬁed in diagnostics. Phenotypes that were previously reported
n ﬂy models of well-established ID disorders, such as synap-
ic, learning and memory defects, have been tested in a number
f Drosophila models of newly identiﬁed ID genes with various
egrees of (human) genetic evidence.
An ID gene that has received support for causality by vari-
us Drosophila phenotypes including synaptic defects and learning
eﬁcits is CEP89,  a gene homozygously deleted in a single patient
ith isolated complex IV deﬁciency, intellectual disability and mul-
isystemic problems (van Bon et al., 2013). Other examples include
he combined approaches of heterozygosity mapping and next-
eneration sequencing that led to the identiﬁcation of ANK3 and
SUN2 as mutated in two forms of autosomal recessive ID. A bal-
nced translocation that disrupts one copy of all ANK3 isoforms in
ne individual, and a homozygous mutation in the longest ANK3
soform in a family were found. The causality of mutations in
NK3 is supported by its previous implication in neuropsychiatricehavioral Reviews 46 (2014) 326–342
disorders in humans and by Drosophila studies revealing a role
for this gene in synapse development (Koch et al., 2008; Pielage
et al., 2008) and memory (Iqbal et al., 2013). One  splice site and
two missense mutations were found in the RNA methyltransferase
NSUN2 gene in patients with autosomal recessive moderate to
severe ID and facial dysmorphism. The Nsun2 ﬂy model shows
severe defects in short-term memory in an olfactory conditioning
paradigm (Abbasi-Moheb et al., 2012).
More recently, candidates with genetic ﬁndings based on whole-
exome sequencing studies have been investigated in Drosophila.
Two loss-of-function mutations (a stop and frameshift) in the chro-
matin modiﬁer GATAD2B were found in exome studies (de Ligt et al.,
2012). These and further investigations showed that mutations
in GATAD2B cause a recognizable ID syndrome and are associ-
ated with learning deﬁcits and synaptic undergrowth in Drosophila
(Willemsen et al., 2013). Thus, rare genetic ﬁndings can signiﬁ-
cantly proﬁt from Drosophila models of their associated disorders.
5.2.2. Support for causality through disease-relevant gene-gene
interactions
Strong support for the causative involvement of a gene in a rec-
ognizable syndrome can also be provided by demonstrating genetic
interactions with an already established disease gene, or with fur-
ther novel candidates identiﬁed. This can make a sufﬁcient case
to reach a genetic diagnosis, even for genetic changes identiﬁed
in single patients, as has recently been demonstrated for Kleefstra
syndrome. In 2006, heterozygous deletions or mutations in EHMT1
were shown to cause this disorder (Kleefstra et al., 2006). However,
defects in EHMT1 are detected in only 25% of all patients with Kleef-
stra syndrome, strongly suggesting the involvement of additional
genes (Kleefstra et al., 2009). By targeted approaches and exome
sequencing, de novo mutations in ﬁve genes were found in four
patients with the core features of Kleefstra syndrome (Kleefstra
et al., 2012). These genes were MLL3, MDB5,  SMARCB1, NR1I3 and
MTMR9; the latter two  genes carried mutations in the same patient.
Sequencing these genes in an additional cohort of 50 patients
did not reveal additional mutations. Therefore, although it was
immediately striking that four of these genes, like EHMT1,  encode
regulators of chromatin, the causality of these mutations remained
to be demonstrated. Available information and pairwise genetic
interaction experiments with Drosophila EHMT in the wing allowed
for the reconstruction of a novel chromatin modiﬁcation mod-
ule with both synergistic and antagonistic interactions (Kleefstra
et al., 2012). Furthermore, a genetic interaction was found between
EHMT and the ortholog of NR1I3,  but not between EHMT and
Drosophila MTMR9. The absence of the latter interaction contributed
to the individual’s diagnosis of a causative mutation in the nuclear
receptor gene. This shows that Drosophila phenotyping can inform
human genetics, and facilitate clinical decision-making. Of  note,
clinical syndromes being genetically heterogeneous is a rule rather
than an exception (Oti and Brunner, 2007). This approach is there-
fore widely applicable.
5.2.3. Analysis of variants
Finally, disease-relevant biological assays to directly assess
the effect of a disease allele/variant are desirable (Zaghloul and
Katsanis, 2010). However, constructs and transgenic ﬂies for such
an approach have to be generated, making it more time-consuming
than loss or gain of function studies using available resources such
as genome-wide inducible RNAi collections and overexpression
stocks. Variants can be investigated in overexpression experiments,
comparing gain-of-function phenotypes evoked by the wild-type
allele to those caused by mutant alleles. This approach has been
used in the early days in ﬂy models of Fragile X syndrome to
determine the consequence of a rare FMR1 point mutation, l367N,
located in the second KH (RNA-binding) domain (Wan  et al., 2000).
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nalogous mutations introduced in either the KH1 or KH2 domain
f the Drosophila ortholog signiﬁcantly ameliorates, but does not
ompletely suppress external and internal eye defects, demonstrat-
ng that this allele represents a partial loss-of-function allele.
Re-expression strategies to rescue a null condition with wild-
ype versus mutant constructs, gene replacement strategies or
enome editing, are more advanced approaches that can be used to
ddress the particular function of an observed variant of interest.
ver- and re-expression approaches can express the human gene
nd variants, or the ﬂy gene with introduced variant, if the affected
mino acid is conserved (Coffee et al., 2012).
. Clinical application of Drosophila II: toward treatment
.1. From reversible phenotypes in models of ID to ﬁrst clinical
rials
ID disorders have long been thought to result from abnormal
rain development rather than from acute deﬁcits in neuronal
unction, because brain function in ID patients is affected at or
oon after birth. They have thus been considered untreatable.
owever, an accumulating body of evidence demonstrates that
ehavioral and cognitive phenotypes in several animal models of
D disorders can be improved or restored at post-embryonic stages.
enetic and/or pharmacologic rescue in adulthood was  success-
ul in mouse models of Neuroﬁbromatosis (NF1), Rett syndrome
MECP2), Rubinstein-Taybi (CBP), Macrocephaly/Autism syndrome
PTEN), Angelman syndrome (UBE3A) and Tuberous sclerosis (TSC1
nd TSC2), reviewed elsewhere (Castrén et al., 2012; Ehninger et al.,
008). After the early ﬁnding that statins, widely used cholesterol-
owering drugs applied to treat hypercholesterolemia, improved
earning and attention deﬁcits in the NF1 mouse model (Li et al.,
005), it took only three years until the ﬁrst report of a random-
zed, controlled trial came out (Krab et al., 2008a). The challenges
ssociated with translating such trials and ﬁndings to humans are
iscussed in (Castrén et al., 2012). Researchers of the Learning Dis-
bilities Network (LeaDNet) and the expertise center ENCORE at
he Erasmus Medical Center (Rotterdam, Netherlands) have estab-
ished competence to facilitate and conduct further clinical trials in
euroﬁbromatosis type 1 and other “reversible” ID disorders men-
ioned previously, notably those associated with the Ras/MAPK and
TOR pathways (Acosta et al., 2012; ENCORE).
Despite these encouraging activities and the impact that they
ave on our view of the molecular nature and temporal origin of
at least some) ID disorders, work in this ﬁeld is still limited. Two
ottlenecks that limit the expansion of investigations in this ﬁeld
re: (1) identifying ID disorders in which behavioral and cognitive
eﬁcit can potentially be restored, and (2) identifying compounds
hat can serve as a starting point for clinical trials. Animal models,
o date primarily mice, have been indispensable in gathering the
nowledge necessary to initiate the ﬁrst steps toward treatment
escribed above. However, generation of mutant mouse models
nd breeding takes considerable time and resources, and therefore
ypically only up to a hand-full of compounds are tested, at least in
cademic settings. Drosophila models are ideally suited as an initial
ool to determine by genetic approaches whether cognitive or other
isease-relevant defects can be rescued by adult re-expression of
 gene in a mutant background, and for targeted drug testing.
oreover, ﬂies can be effectively used for drug screens, much as
he traditional high-throughput screens in pharmaceutical industry
hat are based on in vitro cell culture or biochemical assays.Drosophila has made a major contribution to the identiﬁcation
f pharmacological rescue in Fragile X syndrome. Following the
GluR theory of Fragile X, successful treatment of phenotypes
ncluding learning and memory defects with mGluR5 antagonistsehavioral Reviews 46 (2014) 326–342 335
and lithium was ﬁrst accomplished in the Fragile X ﬂy model (Bear
et al., 2004; McBride et al., 2005). In subsequent years, these com-
pounds have proven to counteract behavioral, morphological and
neurophysiological abnormalities in mutant mice and are currently
being tested in clinical trials (Choi et al., 2011; de Vrij et al., 2008;
Yan et al., 2005). Signiﬁcant improvement of abnormal behaviors
associated with the disease has been reported, at least in a subgroup
of patients (Berry-Kravis et al., 2008; Jacquemont and Curie, 2011).
Further studies are required, particularly with carefully assessed
cognitive outcome measures.
In addition to the targeted approach, an unbiased drug screen
has been carried out in Fragile X ﬂies (Chang et al., 2008). Inter-
estingly, three of the compounds that rescued Fragile X-related
glutamate-induced lethality were positive regulators of GABA
signaling. This made immediate sense, since the GABAergic sys-
tem counteracts glutamatergic excitatory circuits that are overly
active in Fragile X syndrome. This ﬁnding is also in agreement with
previous reports on reduced expression of several GABA-A receptor
subunits, consistently found in the Fragile X mouse and Drosophila
models (D’Hulst et al., 2006; El Idrissi et al., 2005). GABA-A recep-
tor agonists have subsequently revealed beneﬁcial effects in mice.
Ganaxolone is currently in phase II clinical trials for the treatment
of epilepsy and is thus also a promising treatment option for Fragile
X patients (Heulens et al., 2012).
The most recently reported successful adult rescue of a ID dis-
order has been accomplished in the earlier-mentioned Drosophila
model of Kleefstra syndrome. Re-expression of EHMT from a trans-
gene, induced in adult ﬂies, fully restores memory (Kramer et al.,
2011). The epigenetic function and genetic interactions between
EHMT and other Kleefstra syndrome genes (Kleefstra et al., 2012)
provide a lead for future drug testing.
6.2. Disease-relevant outcome measures for high-throughput
drug screens
When it comes to unbiased testing of chemical compounds,
Drosophila offers advantage over classic in vitro screens pursued
by pharmaceutical companies that traditionally have a very high
rate of failure late in the drug development process. Optimized lead
compounds often turn out to be toxic to the complex physiology of
an intact organism, or fail to exhibit the desirable characteristics
for absorption, distribution, metabolism and/or excretion (ADME
properties) (Pandey and Nichols, 2011). Despite their evolutionary
distance to humans, it is likely that Drosophila models can offer
complementary, if not better, information on physiological bene-
ﬁts and side effects of drugs than in vitro systems. As in humans,
the output measure of drug screens in ﬂy (and other animal) mod-
els is likely to be a parameter of great importance for success. The
encouraging ﬁndings of the drug screen in Fragile X ﬂies shows
that even lethality can be used as read-out in a primary screen,
however it should be kept in mind that not every ID gene is essen-
tial or can be sensitized to lethality as in this speciﬁc case (Chang
et al., 2008). More sophisticated output measures that are directly
related to the disease pathology, such as learning or memory, are
desirable. This may  reduce the throughput of a screen to a certain
degree. However, genetic screens for learning and memory mutants
have been performed for decades in Drosophila and novel high-
throughput compatible solutions are emerging, from automated
tracking of ﬂy behavior (Dankert et al., 2009; Dubnau and Tully,
1998; Skoulakis and Grammenoudi, 2006; Valente et al., 2007) to
complete (commercially available) set-ups such as Aktogen’s Auto-
jump system (Sharma et al., 2009). Testing mutant conditions in a
similar paradigm, Drosophila light-off jump habituation has already
revealed defects in non-associative learning in several Drosophila
models of ID (Kramer et al., 2011; van Bon et al., 2013; Willemsen
et al., 2013). It is to be hoped that such solutions will ultimately be
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dopted by the pharmaceutical industry in academic and private
artnerships to advance drug testing for ID and related disorders.
.3. Summary and future direction: “network medicine”
It appears unrealistic to speculate, based on a dozen studies
n animal models (Castrén et al., 2012; Ehninger et al., 2008),
hat cognitive deﬁcits can be potentially reversed in the majority
f ID disorders. Yet, the previously listed ﬁndings are intriguing
nd raise hope that a signiﬁcant number of such conditions exist.
ikewise, it seems unlikely that cognitive impairment in humans
an be cured, and we therefore believe that this term should
e avoided not to raise expectations above the realistic. How-
ver, treatment that helps to improve cognitive and/or behavioral
unctioning, potentially in combination with environmental stimu-
ation, would represent a major step forward for patients and their
amilies (Castrén et al., 2012). Great effort should thus be invested
n better understanding the molecular neurobiology that underlies
ndividual or groups of ID disorders and in the translation of such
nowledge to the clinics.
Despite the socio-economic importance of ID and its high preva-
ence in the general population, the vast majority of ID disorders
re rare, in fact too rare to receive attention from the pharmaceuti-
al industry. Therefore, it is to be expected that academic research,
atient foundations and public funding have to drive progress in
his ﬁeld. Because of the immense costs of developing new drugs,
esting/screening drugs that are already FDA-approved appears
o be the most promising road forward at present. Moreover,
ccumulating insights into molecular mechanisms that are shared
mong ID disorders can be envisioned to provide the opportunity
o target genetically heterogeneous patients with a common treat-
ent. Such shared mechanisms can represent either compromised
olecular networks, or more broadly compromised molecular pro-
esses. For example, among ID disorders there are at least a dozen
enetic conditions that are due to mutations in components or
egulators of the mitochondrial oxidative phosphorylation machin-
ry. Oxidative phosphorylation is also affected in additional ID
isorders (Haddad et al., 2013; Kriaucionis et al., 2006; van Bon
t al., 2013), making approaches to improve or bypass defects in
his process an attractive common theme for treatment. Molecular
etworks – signaling pathways or other protein–protein interac-
ion modules – can likewise provide a common ground to target
ultiple conditions. The above discussed chromatin modiﬁcation
odule underlying Kleefstra spectrum disorders and Rasopathies
re only some examples. The ﬁrst large-scale functional approach to
D in Drosophila has identiﬁed 26 phenotypically coherent modules
phenoclusters) using morphological eye and functional pheno-
yping. Interestingly, a validated cluster of eight ID genes has
uccessfully predicted novel roles in synapse development for three
f these genes. This cluster also includes PTEN and TSC2, two ID
enes whose associated cognitive defects are reversible, making the
ix other genes in the same cluster (MYO5A, MYCN,  RPS6KA3, DMD,
IGV and UPF3B),  prime candidates for cognitive proﬁling, adult res-
ue experiments and, if successful, drug trials (Oortveld et al., 2013).
rosophila research is likely to contribute to such efforts.
. From modeling monogenic forms of ID to modeling
ligogenic ID and multifactorial cognitive disorders
.1. Cognitive disorders of multifactorial inheritance.1.1. Emerging evidence for oligogenic ID
The identiﬁcation of genes for ID has been most success-
ul for disorders that display a monogenic inheritance pattern,
any of which have been identiﬁed by genetic linkage in largeehavioral Reviews 46 (2014) 326–342
consanguineous families. A large number of cases remain unsolved,
but with the recent advent of exome sequencing, many cases of
sporadic ID have been found to be monogenic as well, with a sig-
niﬁcant contribution of de novo mutations (Ku et al., 2013; Veltman
and Brunner, 2012; Vissers et al., 2010). However, not all cases of
ID display monogenic patterns of inheritance. Whereas severe de
novo mutations are often limiting fecundity and thus remain rare
in populations, weaker mutations can be more common and result
in more complex inheritance patterns (de Ligt et al., 2012; Rauch
et al., 2012).
Exome sequencing, and probably soon whole-genome sequenc-
ing, provide new opportunities – and enormous challenges – in
uncovering complex patterns of inheritance underlying a fraction
of ID disorders. Particularly in the mild spectrum of ID (IQ ∼50–70),
an oligogenic or multifactorial inheritance is likely much more fre-
quent than currently appreciated and may  account for a signiﬁcant
proportion of still unsolved cases of ID. For instance Bardet-Biedl
syndrome, which is associated with ID, is inherited in a classic
recessive pattern, but di- and trigenic inheritance has been demon-
strated in some cases (Katsanis et al., 2001). In total 15 genes
have been identiﬁed of which different combinations were found
to segregate in families (Badano et al., 2006; Beales et al., 2003;
Billingsley et al., 2010; Bin et al., 2009; Chen et al., 2011; Fauser
et al., 2003; Hjortshøj et al., 2010; Katsanis et al., 2002). Other exam-
ples of ID disorders with partly complex inheritance are Dent’s
disease (co-inheritance of OCRL and CLCN5 mutations) (Addis et al.,
2013), Holoprosencephaly (SHH with either ZIC2 or TGIF1) (Ming
and Muenke, 2002; Nanni et al., 1999), Rasopathy (PTPN11 and
SOS1) (Fahrner et al., 2012) and other forms of ID (MECP2 and ATRX;
SHANK2 and CHRNA7; NRXN1 and various) (Béna et al., 2013; Chilian
et al., 2013; Honda et al., 2012; Leblond et al., 2012), or ID with
co-morbid ASD (FOXP1 and CNTNAP2) (O’Roak et al., 2011).
These examples illustrate that genes that have so far been
implicated in oligogenic ID are, with few exceptions, identical to
monogenic ID genes. This suggests that it is not the genes but
the strength of particular mutations that dictate whether addi-
tional factors are required for disease presentation. The above
listed examples also illustrate that oligogenic inheritance is based
on gene-gene interactions that occur among genes that act in
the same molecular network. While striking in the gene pairs
reported above, (e.g. OCRL and CLCN5 are implicated in endocy-
tosis (Devuyst et al., 1999; Erdmann et al., 2007), ZIC2 and TGIF1
interfere with SHH signaling (Ming and Muenke, 2002; Nanni et al.,
1999), PTPN11 and SOS1 both act in Ras/MAPK signaling pathways
(Fahrner et al., 2012), MECP2 and ATRX chromatin proteins directly
interact with each other (Nan et al., 2007), CNTNAP2 is a target
gene of FOXP1 (O’Roak et al., 2011)), the extent to which these two
themes will apply in general is unknown. At present the ﬁeld of
oligogenic inheritance is strongly dependent on hypothesis-driven
data interpretation based on exactly these two  themes (known dis-
ease associations and functional connections between candidates).
The current view is surely highly biased.
Gene-gene interactions and additive effects are also likely to be
contributing to neuropathology caused by copy-number variations,
which also play a prominent role in ID. Our current knowledge of
oligogenic causes of ID may  only represents the tip of the iceberg.
This scenario resembles the complexity and challenges of unravel-
ing the genetics of neuropsychiatric disorders.
7.1.2. Genetic overlap between ID and neuropsychiatric disorders
Not only do some ID disorders share a oligogenic etiology with
neuropsychiatric disorders, they also appear to (partly) share their
underlying genetic architecture. The genetic overlap may  in part be
the result of the same pathogenic genes, but different genetic aber-
rations. While individual ID disorders are rare in the population,
neuropsychiatric disorders are common. The most common cause
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Fig. 3. Genetic overlap of ID and neuropsychiatric disorders. Monogenic disorders
often arise from rare mutations that have a severe impact on gene function, while
multifactorial disorders often arise from common variants with a weaker severity.
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Fig. 4. Publications reporting Drosophila models of neurodegenerative, intellectual
disability, and neuropsychiatric disorders. Publications mentioning Drosophila mod-raX, Fragile X syndrome; BBS, Bardet-Biedl syndrome; NS, Noonan syndrome;
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ttention-deﬁcit/hyperactivity disorder; MDD, major depressive disorder.
f inherited ID is Fragile X syndrome and occurs in 1/5000 males,
hile attention-deﬁcit/hyperactivity disorder (ADHD) is diagnosed
n 13% of boys. Interestingly, ADHD is one of the most frequently
ecognized disorders associated with Fragile X syndrome: 54–59%
f boys with Fragile X syndrome meet diagnostic behavioral crite-
ia for ADHD (Sullivan et al., 2006). It is intriguing to consider that
imilar pathways are disturbed in Fragile X and ADHD. While Frag-
le X is a disorder with a severe mutation in a single gene, ADHD is
ypothesized to be the accumulated effect of multiple weaker gene
ariations (Fig. 3).
Multifactorial disorders overlap in their genetics as well, as
hown for childhood ADHD and adult Schizophrenia, or suggested
y the recent cross-disorder study that reported shared genetic
elationship between ﬁve major psychiatric disorders (Psychiatric
enomics Consortium et al., 2013; Hamshere et al., 2013). As is rec-
gnized at the start of the DSM-5 (Adam, 2013) and by the NIMH
esearch Domain Criteria project (Morris and Cuthbert, 2012), psy-
hiatric disorders should be seen as dimensional traits that share
iological overlap rather than being classiﬁed as distinct groups.
nvironment and genetic modiﬁers can signiﬁcantly modulate the
nal disease presentation.
Gene identiﬁcation studies for complex genetic or multifacto-
ial disorders still greatly lag behind classical Mendelian ones, but a
trong genetic component has been established for many neuropsy-
hiatric disorders through twin and adoption studies. For example,
he heritability of the relatively common ASD is estimated to be
0% and ADHD 75–90% (Elia et al., 2012; Faraone et al., 2005; Wood
t al., 2008), but the identiﬁcation of genetic factors is not straight-
orward, resulting in the concept of missing heritability (Bailey
t al., 1995; Elia et al., 2012; Faraone et al., 2005; Manolio et al.,
009; Wood et al., 2008). The mutations underlying these disor-
ers are thought to have a small effect size and be common in the
opulation, making their identiﬁcation a challenge.
Nonetheless research has been successful in uncovering impor-
ant genetic factors for presumably multifactorial traits. Thisels  of neurodegenerative disorders have increased linearly over the past decade,
while ID models have taken off since 2007 after a preceding wave of reviews. In
recent years the modeling of neuropsychiatric disorders is receiving increasing
attention.
applies to ADHD-like characteristics that are comorbid with a wide
variety of monogenic ID disorders such as Fragile X syndrome,
Tuberous Sclerosis, Neuroﬁbromatosis I and other Rasopathies, and
multigenic ID conditions such as Williams Syndrome (Curatolo
et al., 2009). Additionally, autistic traits are often co-morbid with
monogenic ID disorders such as Fragile X syndrome or Tuberous
Sclerosis (Zafeiriou et al., 2007). Modeling monogenic ID to under-
stand their molecular/cellular/developmental basis is thus likely to
provide insights into oligogenic forms of ID and into other neu-
ropsychiatric disorders. Drosophila is an excellent model system
to study complex genetic interactions that underlie multifactorial
disorders, because of its strength in combinatorial genetics and the
wide range of established behavioral paradigms.
7.2. Drosophila as a model for multifactorial cognitive disorders
Modeling neuropsychiatric disorders in Drosophila stands now
where modeling of ID was around 10 years ago: its successful appli-
cation is still very limited, but it is receiving increasing attention.
Drosophila models of neuropsychiatric disorders are increasingly
discussed in the literature although these are, at present, more
reviews than research papers (van Alphen and van Swinderen,
2011), just as it was the case in the ﬁrst years of this millennium
for ID (see Fig. 4). Many opportunities and challenges in this ﬁeld
lie ahead.
When variants in multiple genes are identiﬁed in oligogenic
forms of ID and psychiatric genetics, it is hard to prove the causative
nature of the mutations. The families often show incomplete pen-
etrance, or multiple combinations segregate. Drosophila provides
the excellent opportunity to perform gene-gene/protein-protein
interaction studies, which can test the hypothesis of the oligogenic
inheritance found in humans. Of note, such experiments can be car-
ried out under conditions that control for genetic background and
environmental factors, reducing the impact of confounding factors
on the phenotype.
An example of uncovering a protein-protein interaction
involved in both ID and neuropsychiatric disorder is the E3 ubiqui-
tin ligase protein UBE3A, which is mutated in Angelman syndrome
and overexpressed in 15q duplication Autism. A proteomic screen
in Drosophila revealed that Ube3a regulates the actin cytoskeleton
and neuronal homeostasis. Ube3a was found to ubiquitinate the
Autism-associated Na+/K+ pump ATP, stimulating new avenues
of research in ﬂy and mouse models of Angelman syndrome and
Autism (Jensen et al., 2013).
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for  Pitt-Hopkins syndrome, a severe epileptic encephalopathy associated with
autonomic dysfunction. Am.  J. Hum. Genet. 80, 988–993.
Anderson, G.R., Galﬁn, T., Xu, W.,  Aoto, J., Malenka, R.C., Sudhof, T.C., 2012. Candidate38 M. van der Voet et al. / Neuroscience an
In few cases monogenic heritable neuropsychiatric disor-
ers have been studied in Drosophila,  such as disrupted-in-
chizophrenia-1 (DISC1), one of the major susceptibility factors for
 wide range of mental illnesses, including Schizophrenia, Bipo-
ar Disorder, Major Depression and Autism Spectrum conditions
Sawamura et al., 2008). Expression of human DISC1 in Drosophila
esults in punctate localization of the protein in the nucleus, which
as validated in primary mammalian neuron cultures. The trans-
enic ﬂies display defects of sleep homeostasis consistent with
ltered CREB signaling. Indeed, DISC1 was found to modulate CRE-
ediated gene transcription through interaction with ATF4/CREB2.
creening for genetic interactors that normalize or enhance the
ISC1-induced sleep alteration would be of great interest.
Misregulation of the ortholog of the Schizophrenia suscepti-
ility gene dysbindin (DTNBP1) revealed its regulatory function
f glutamatergic and dopaminergic signaling, and with genetic
ools exclusively available in Drosophila,  two independent mecha-
isms could be identiﬁed that lead to clinically relevant behavioral
henotypes (Shao et al., 2011). First, reduced expression of dys-
indin in presynaptic neurons suppresses glutamatergic synaptic
ransmission, which results in impaired memory. Second, reduced
xpression of dysbindin in glial cells causes hyperdopaminergic
ctivities that lead to abnormal locomotion. Both behaviors can
e rescued with acute genetic or pharmacological treatments in
dults, suggesting that genetically relevant phenotypes in humans
ould be reversible.
Neuroligins have been implicated in ID and ASDs, together with
everal other components (Neurexins and Shanks) of the trans-
ynaptic signaling machinery. Deletion of Drosophila Neuroligin 2
mpairs social interactions, alters acoustic communication signals,
nd affects the transition between different behaviors, resembling
ome core symptoms of ASDs (Hahn et al., 2013).
To facilitate translational research including drug testing, it
ould be an important achievement to develop or optimize behav-
or assays that parallels mouse and human behavior as closely as
ossible, yet can be conducted in higher throughput. For oligogenic
isorders it will be important (compared to successful monogenic
D models) to be able to control efﬁciency of gene manipulation
ore tightly and to apply highly sensitive assays. Not necessar-
ly, but ideally, such assays would test speciﬁc cognitive domains
nd recapitulate selective aspects of behavioral problems seen in
he disorders. The spectrum of behaviors that can be assayed in
rosophila is constantly increasing. These include non-associative
nd associative learning and memory, social behavior, aggression,
ocial interaction, decision-making, activity and sleep, and addic-
ion (Anholt and Mackay, 2012; Billeter and Levine, 2013; Davis,
011; Harbison et al., 2009; Maimon et al., 2008; Ojelade and
othenﬂuh, 2009; Pavlou and Goodwin, 2013; Sokolowski, 2010).
odeling neuropsychiatric disorders in Drosophila is still in its
nfancy, but it can be anticipated that such neuropsychiatric models
ill ‘ﬂy off’ soon.
. Concluding remarks
With this review, we have aimed to provide an overview on
he contribution that Drosophila research has made to date to
ur understanding of ID disorders and of the molecular control
f cognition. Bridging the gap between fundamental and clinical
esearch is of high important and societal signiﬁcance as it can
peed up scientiﬁc and medical progress. Researchers studying
rosophila and human biology can proﬁt greatly from mutualisms:
henotypes of human conditions can indicate similar underlying
athologies to be investigated in Drosophila,  while on the other
and clinical researchers can greatly beneﬁt from the fundamental
nowledge that has been acquired in the past century in Drosophilaehavioral Reviews 46 (2014) 326–342
(Bellen et al., 2010). However, mutualism requires awareness of
knowledge/publications in both ﬁelds, which is not always straight-
forward when genes are named differently across species. The
Ensembl genome browser (www.ensembl.org) functions as a broad
platform and has a great resource for quick retrieval of orthologs,
using the comparative genomics pages that utilize phylogenetic
trees to cluster homologs (Flicek et al., 2013). Orthologs can be
found in the Ensembl gene-based display, or retrieved through
a BioMart query (Vilella et al., 2009). Reversely, the database
of Drosophila genes and genomes (FlyBase, www.ﬂybase.org) has
recently implemented an orthology section (Marygold et al., 2013)
that makes it easy for Drosophila researchers to identify human
orthologs. The FlyBase gene summary pages also contain gene
function and phenotype summaries and publication lists that are
informative for human geneticists and clinicians.
Here, we focused on the opportunities, not limitations, that we
see and predict for Drosophila as a model, particularly for transla-
tional research in future medical genomics. It is not our opinion
that Drosophila is superior to other genetic model organisms such
as worm,  zebraﬁsh and mouse. On the contrary, particularly ver-
tebrate models provide an important and indispensable bridge to
translate the insights gained in Drosophila into future applications
that will improve diagnosis, personalized patient support and treat-
ment.
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